BRIEF-Sanofi, Teva Say Duvakitug Positive Phase 2B Results Show Best-In-Class Potential

Reuters12-17

Dec 17 (Reuters) - Sanofi SA :

* DUVAKITUG POSITIVE PHASE 2B RESULTS DEMONSTRATE BEST-IN-CLASS POTENTIAL IN ULCERATIVE COLITIS AND CROHN'S DISEASE

* 47.8% OF UC PATIENTS ON HIGH DOSE DUVA KITUG ACHIEVED CLINICAL REMISSION

* SANOFI AND TEVA TO INITIATE PHASE 3 DEVELOPMENT IN IBD

* TEVA TO LEAD COMMERCIALIZATION IN EUROPE, ISRAEL AND OTHER COUNTRIES

* SANOFI TO LEAD COMMERCIALIZATION IN NORTH AMERICA, JAPAN, ASIA AND REST OF WORLD

* 47.8% OF CD PATIENTS ON HIGH DOSE DUVA KITUG ACHIEVED ENDOSCOPIC RESPONSE

Source text: Further company coverage:

(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492595916?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-17 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492595916","market":"us","top_or_hot":-1,"title":"BRIEF-Sanofi, Teva Say Duvakitug Positive Phase 2B Results Show Best-In-Class Potential","media":"Reuters","content":"<html><body><p>Dec 17 (Reuters) - <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> SA   :</p><p>   * DUVAKITUG POSITIVE PHASE 2B RESULTS DEMONSTRATE BEST-IN-CLASS POTENTIAL IN ULCERATIVE COLITIS AND CROHN'S DISEASE</p><p>   * 47.8% OF UC PATIENTS ON HIGH DOSE DUVA KITUG ACHIEVED CLINICAL REMISSION</p><p>   * SANOFI AND TEVA TO INITIATE PHASE 3 DEVELOPMENT IN IBD</p><p>   * TEVA TO LEAD COMMERCIALIZATION IN EUROPE, ISRAEL AND OTHER COUNTRIES</p><p>   * SANOFI TO LEAD COMMERCIALIZATION IN NORTH AMERICA, JAPAN, ASIA AND REST OF WORLD</p><p>   * 47.8% OF CD PATIENTS ON HIGH DOSE DUVA KITUG ACHIEVED ENDOSCOPIC RESPONSE</p><p>Source text:    Further company coverage:   </p><p> (Gdansk Newsroom)</p><p>((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sanofi, Teva Say Duvakitug Positive Phase 2B Results Show Best-In-Class Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sanofi, Teva Say Duvakitug Positive Phase 2B Results Show Best-In-Class Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 20:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dec 17 (Reuters) - Sanofi SA   :   * DUVAKITUG POSITIVE PHASE 2B RESULTS DEMONSTRATE BEST-IN-CLASS POTENTIAL IN ULCERATIVE COLITIS AND CROHN'S DISEASE   * 47.8% OF UC PATIENTS ON HIGH DOSE DUVA KITUG ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNYNF","symbol_name":"Sanofi","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2492595916","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492595916","pubTimestamp":1734439079,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Dec 17  - Sanofi SA   :   * DUVAKITUG POSITIVE PHASE 2B RESULTS DEMONSTRATE BEST-IN-CLASS POTENTIAL IN ULCERATIVE COLITIS AND CROHN'S DISEASE   * 47.8% OF UC PATIENTS ON HIGH DOSE DUVA KITUG ACHIEVED CLINICAL REMISSION   * SANOFI AND TEVA TO INITIATE PHASE 3 DEVELOPMENT IN IBD   * TEVA TO LEAD COMMERCIALIZATION IN EUROPE, ISRAEL AND OTHER COUNTRIES   * SANOFI TO LEAD COMMERCIALIZATION IN NORTH AMERICA, JAPAN, ASIA AND REST OF WORLD   * 47.8% OF CD PATIENTS ON HIGH DOSE DUVA KITUG ACHIEVED ENDOSCOPIC RESPONSESource text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNYNF":"Sanofi","BK4007":"制药"},"translate_title":"简介-赛诺菲、梯瓦表示Duvakitug 2b期阳性结果显示出一流的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1},"content_text":"Dec 17 (Reuters) - Sanofi SA   :   * DUVAKITUG POSITIVE PHASE 2B RESULTS DEMONSTRATE BEST-IN-CLASS POTENTIAL IN ULCERATIVE COLITIS AND CROHN'S DISEASE   * 47.8% OF UC PATIENTS ON HIGH DOSE DUVA KITUG ACHIEVED CLINICAL REMISSION   * SANOFI AND TEVA TO INITIATE PHASE 3 DEVELOPMENT IN IBD   * TEVA TO LEAD COMMERCIALIZATION IN EUROPE, ISRAEL AND OTHER COUNTRIES   * SANOFI TO LEAD COMMERCIALIZATION IN NORTH AMERICA, JAPAN, ASIA AND REST OF WORLD   * 47.8% OF CD PATIENTS ON HIGH DOSE DUVA KITUG ACHIEVED ENDOSCOPIC RESPONSESource text:    Further company coverage:    (Gdansk Newsroom)((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492595916"}